Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
|Deserunt mollit sunt Lorem laborum do id aliqua dolore||14 Jul 2022||Lorem|
|NIH’s hIVIG trial in hospitalized COVID-19 patients close to meeting recruitment target; outpatient study planned for start in next few months, sources say||29 Jan 2021||Manasi Vaidya|
|hIVIG trials to hurt from convalescent plasma use in COVID-19; manufacturing limitations to likely present hurdles, experts say||28 Oct 2020||Manasi Vaidya|
|hIVIG efforts likely to outdo convalescent plasma in COVID-19, but efficacy magnitude unclear with background use of Gilead’s Veklury, experts say||27 Oct 2020||Manasi Vaidya|
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Insight on companies’ CRO and business development needs, strategies and relationships
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer